Clinical trial · no report yet · Phase 3

QUINTESSENTIAL-2

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479 ↗
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Standard

We haven't built an HCP commentary report on QUINTESSENTIAL-2 (arlocabtagene autoleucel (BMS-986393) in lenalidomide-exposed relapsed or refractory multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on QUINTESSENTIAL-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Channel	Indexed
YouTube	8
X threads	5
Podcasts	2

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma
Phase: Phase 3
Status: Recruiting
Conditions: Relapsed or Refractory Multiple Myeloma (RRMM)
Interventions: BMS-986393; Cyclophosphamide; Fludarabine; Daratumumab; Pomalidomide; Dexamethasone; Carfilzomib
Arms: Arm A · Experimental
Arm B · Active comparator
Enrollment: 440 (estimated)
Primary outcomes: Progression Free Survival (PFS)
Minimal residual disease (MRD)-negativity in complete response (CR)
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company with Celgene Corporation
Start: Mar 12, 2025
Primary completion: Dec 30, 2027 (estimated)
Results posted: No
Registry record: NCT06615479 · updated Oct 29, 2026